On the public citation graph

https://doi.org/10.2139/ssrn.4647301

0 signed · 30 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1006/jmbi.1996.0897openalex-extracted
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
inferredcites →https://doi.org/10.1007/bf00124324openalex-extracted
A genetic algorithm for flexible molecular overlay and pharmacophore elucidation
inferredcites →https://doi.org/10.1007/s10549-018-5023-4openalex-extracted
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
inferredcites →https://doi.org/10.1016/j.apsb.2023.05.005openalex-extracted
Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer
inferredcites →https://doi.org/10.1016/j.cbpa.2019.02.022openalex-extracted
Targeted protein degradation: elements of PROTAC design
inferredcites →https://doi.org/10.1016/j.cellin.2022.100030openalex-extracted
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
inferredcites →https://doi.org/10.1016/j.chembiol.2021.08.004openalex-extracted
A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells
inferredcites →https://doi.org/10.1016/j.ejmech.2020.112539openalex-extracted
PROTAC: A promising technology for cancer treatment
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113814openalex-extracted
Indomethacin-based PROTACs as pan-coronavirus antiviral agents
inferredcites →https://doi.org/10.1016/j.pharmthera.2023.108350openalex-extracted
Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression
inferredcites →https://doi.org/10.1016/j.snb.2018.06.022openalex-extracted
Estrogen receptor sensing in living cells by a high affinity turn-on fluorescent probe
inferredcites →https://doi.org/10.1016/j.soncn.2015.02.002openalex-extracted
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
inferredcites →https://doi.org/10.1016/j.steroids.2014.06.012openalex-extracted
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
inferredcites →https://doi.org/10.1021/acs.jmedchem.2c01243openalex-extracted
Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT
inferredcites →https://doi.org/10.1021/acs.jmedchem.2c02032openalex-extracted
Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In Vivo
inferredcites →https://doi.org/10.1021/acschemneuro.3c00096openalex-extracted
PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease
inferredcites →https://doi.org/10.1021/acsptsci.2c00109openalex-extracted
PROTAC Degrader of Estrogen Receptor α Targeting DNA-Binding Domain in Breast Cancer
inferredcites →https://doi.org/10.1021/jm058173sopenalex-extracted
ERβ Ligands. 3. Exploiting Two Binding Orientations of the 2-Phenylnaphthalene Scaffold To Achieve ERβ Selectivity
inferredcites →https://doi.org/10.1038/39645openalex-extracted
Molecular basis of agonism and antagonism in the oestrogen receptor
inferredcites →https://doi.org/10.1038/onc.2008.320openalex-extracted
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
inferredcites →https://doi.org/10.1038/s41573-019-0047-yopenalex-extracted
Targeted protein degradation: expanding the toolbox
inferredcites →https://doi.org/10.1038/s41589-018-0055-yopenalex-extracted
Plasticity in binding confers selectivity in ligand-induced protein degradation
inferredcites →https://doi.org/10.1071/ch9842545openalex-extracted
A synthesis of 2,4-dihydroxyisoflavans and 2-Hydroxyisoflav-3-enes: Versatile precursors to isoflavanoids
inferredcites →https://doi.org/10.1073/pnas.141230798openalex-extracted
Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation
inferredcites →https://doi.org/10.1080/13543776.2021.1840553openalex-extracted
The therapeutic potential of PROTACs
inferredcites →https://doi.org/10.1200/jco.2022.40.16_suppl.tps1120openalex-extracted
ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study.
inferredcites →https://doi.org/10.1200/jco.2022.40.6_suppl.017openalex-extracted
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
inferredcites →https://doi.org/10.3390/ijms23126630openalex-extracted
Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening
inferredcites →https://doi.org/10.3390/vaccines11020270openalex-extracted
Recent Advances in PROTAC-Based Antiviral Strategies
inferredcites →https://doi.org/10.4155/fmc-2021-0206openalex-extracted
Designing HDAC-PROTACs: Lessons Learned So Far
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.